Email: cspc@cspc.cn
Media
News Center
Oct. 28
2026
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6077 INJECTION FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS OFFICIALLY INITIATED AT THE FIRST CENTRE IN
Oct. 26
VOLUNTARY ANNOUNCEMENT - UPDATED OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB FOR THE TREATMENT OF HER2-POSITIVE ADVANCED GASTRI
VOLUNTARY ANNOUNCEMENT - RESULTS FROM A PHASE III CLINICAL STUDY OF ANBENITAMAB IN COMBINATION WITH DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE FIR
Oct. 23
VOLUNTARY ANNOUNCEMENT - BATOCLIMAB INJECTION (SUBCUTANEOUS INJECTION) OBTAINS DRUG REGISTRATION CERTIFICATE FROM THE NMPA
Oct. 22
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2066 FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION OFFICIALLY INITIATED IN CHINA
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE FIRST-LINE TREATMENT OF UNRESECTABLE RECURRENT OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us